Cardiff Lexington Corporation Reports 23.8% Revenue Decline and $3.09 Million Net Loss in Q1 2026

Cardiff Lexington Corporation reported a significant decline in financial performance for the first quarter of 2026, with total revenue decreasing by 23.8% to $2.22 million, down from $2.92 million in the same period last year. The company's gross profit also fell by 28.4% to $1.32 million, resulting in a gross margin of 59.3%, compared to 63.1% in the prior year. The decrease in revenue was attributed to a reduction in surgical procedures and a drop in the settlement realization rate, which fell to 41% from 44% year-over-year.

Operating expenses surged to $1.83 million, up from $1.30 million in the previous year, primarily due to a new share-based compensation expense of $664,196, which was not present in the prior year. This increase in expenses contributed to a loss from operations of $511,159, contrasting with an income of $543,934 in the first quarter of 2025. The net loss for the quarter was $3.09 million, a substantial increase from the $450,777 loss reported in the same quarter last year.

In terms of strategic developments, Cardiff Lexington has been active in financing activities, raising $845,000 through the issuance of convertible notes during the quarter. The company also reported a notable increase in its line of credit, which rose to $18.92 million from $17.21 million at the end of 2025. The total liabilities decreased to $24.63 million from $26.01 million, largely due to the reclassification of certain preferred stock from mezzanine equity to permanent equity, which improved the company's stockholders' equity position to $3.88 million from a deficit of $2.47 million.

Operationally, Cardiff Lexington's healthcare segment, Nova Ortho and Spine, continues to be the primary revenue driver, although it has faced challenges in patient volume and settlement rates. The company has maintained a focus on its core business of providing orthopedic services, primarily to uninsured patients involved in legal claims. As of March 31, 2026, the company had $683,507 in cash, which it believes will be sufficient to fund operations for at least the next year, although additional capital will be necessary for future acquisitions and to support ongoing operations.

Looking ahead, Cardiff Lexington's management has expressed optimism about securing additional financing to support its growth strategy, which includes acquiring more healthcare businesses. However, the company acknowledges the risks associated with its current financial position and the need for effective capital management to ensure continued operations and potential profitability in the future.